Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.

"CONFLICTS OF INTEREST Neehar D. Parikh served as a consultant for Bristol Myers‐Squibb, Exact Sciences, Eli Lilly; has served on advisory boards of Genentech, Eisai, Bayer, Exelixis, and Wako/Fujifilm; and has received institutional research funding from Bayer, Target, Genentech, Exact Sciences, and Glycotest. Neil Mehta served on the advisory boards of Exelixis and Wako/Fujifilm and has received research funding from Target, Wako/Fujifilm, and Glycotest. Ju Dong Yang has served as a consultant for Exact Sciences, Gilead Sciences, and Eisai. Binu John has served on advisory board for Dova and has received institutional research funding from Bristol‐Myers Squibb, Exelixis, H3B biosciences, Glycotest, Glaxo Smithkline, and Viking Therapeutics. Anjana Pillai currently serves on a medical advisory board for Genentech, Eisai, Exelixis, and Replimune; and is a speaker for Simply Speaking Hepatitis (CME). Reena J. Salgia has served on advisory boards for Bayer, Eisai, and Exelixis. Matthew J. Schipper has served as a consultant to Innovative Analytics. Amit G. Singal has served as a consultant or on advisory boards for Genentech, Bayer, Eisai, AstraZeneca, Exelixis, Bristol Meyers Squibb, FujiFilm Wako Diagnostics, Exact Sciences, Roche, Glycotest, and GRAIL. Andrew M. Moon reports consulting fees for work on TARGET HCC. The other authors made no disclosures."

"Funding information National Insitutes of Health, Grant/Award Numbers: U01 CA230694, R01 MD012565, and U01 CA230669."